Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Results of Operations
LLY logo

Eli Lilly Revenue Soars 56% to $19.8 Billion Driven by Massive Demand for Cardiometabolic Drugs

LLY10-QFiling Date: 4/30/2026
Eli Lilly and Company
Description

What this story covers

Eli Lilly reported a record-breaking quarter with $19.8 billion in revenue, fueled by a 125% surge in Mounjaro sales. The company is aggressively expanding manufacturing and R&D while navigating new U.S. drug pricing regulations and global supply demands.

Story snapshot

CompanyEli Lilly and Company
TickerLLY
VariantStandard detailed
Duration12:23
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000059478-26-000045
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in